Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q96M96: Variant p.Met298Arg

FYVE, RhoGEF and PH domain-containing protein 4
Gene: FGD4
Feedback?
Variant information Variant position: help 298 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Methionine (M) to Arginine (R) at position 298 (M298R, p.Met298Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (M) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CMT4H; found in patient's fibroblasts but absent from peripheral nerve where splicing defects and aberrant transcripts are detected. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 298 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 766 The length of the canonical sequence.
Location on the sequence: help EWETTPRIGDILQKLAPFLK M YGEYVKGFDNAMELVKNMTE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         EWETTPRIGDILQKLAPFLKMYGEYVKGFDNAMELVKNMTE

Mouse                         EWETTPRIGDILQKLAPFLKMYGEYVKGFDNAVELVKTMTE

Rat                           EWETTPRIGDILQKLAPFLKMYGEYVKGFDNAVELVKNMTE
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 766 FYVE, RhoGEF and PH domain-containing protein 4
Domain 206 – 393 DH
Alternative sequence 208 – 766 Missing. In isoform 3.



Literature citations
Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot-Marie-Tooth type 4H.
Delague V.; Jacquier A.; Hamadouche T.; Poitelon Y.; Baudot C.; Boccaccio I.; Chouery E.; Chaouch M.; Kassouri N.; Jabbour R.; Grid D.; Megarbane A.; Haase G.; Levy N.;
Am. J. Hum. Genet. 81:1-16(2007)
Cited for: INVOLVEMENT IN CMT4H; VARIANTS CMT4H ARG-298 AND THR-298; TISSUE SPECIFICITY; ALTERNATIVE SPLICING; Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4.
Stendel C.; Roos A.; Deconinck T.; Pereira J.; Castagner F.; Niemann A.; Kirschner J.; Korinthenberg R.; Ketelsen U.-P.; Battaloglu E.; Parman Y.; Nicholson G.; Ouvrier R.; Seeger J.; De Jonghe P.; Weis J.; Kruettgen A.; Rudnik-Schoeneborn S.; Bergmann C.; Suter U.; Zerres K.; Timmerman V.; Relvas J.B.; Senderek J.;
Am. J. Hum. Genet. 81:158-164(2007)
Cited for: INVOLVEMENT IN CMT4H; VARIANT CMT4H ARG-298;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.